TEVIMBRA approuvé aux États-Unis pour le traitement de première intention du carcinome épidermoïde de l'œsophage avancé en association avec la chimiothérapie
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy ?
Source: Businesswire
FDA Approval of TEVIMBRA: BeiGene, Ltd. has received FDA approval for TEVIMBRA® (tislelizumab-jsgr) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) expressing PD-L1 (≥ 1), based on significant survival improvements shown in the RATIONALE-306 study.
Safety and Adverse Effects: The approval highlights the importance of monitoring for serious immune-mediated adverse reactions associated with TEVIMBRA, including pneumonia, colitis, and thyroid disorders, which may require treatment interruptions or discontinuations depending on severity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
